Shitara, Kohei http://orcid.org/0000-0001-5196-3630
Hara, Hiroki
Yoshikawa, Takaki
Fujitani, Kazumasa
Nishina, Tomohiro
Hosokawa, Ayumu
Asakawa, Takashi
Kawakami, Satoe
Muro, Kei
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd.
Article History
Received: 13 August 2019
Accepted: 29 September 2019
First Online: 16 October 2019
Compliance with ethical standards
:
: All authors received support for third-party writing assistance for this manuscript, furnished by Katie Wilson, PhD, of Health Interactions, funded by Chugai Pharmaceutical Co., Ltd. Kohei Shitara received grants and consultancy fees from Astellas Pharma, Eli Lilly, Ono Pharmaceutical, and Merck Sharp & Dohme, grants from Sumitomo Dainippon Pharma, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, and Medi Science, consultancy fees from Bristol-Myers Squibb, Takeda, and Pfizer, and honoraria from Novartis, AbbVie, and Yakult; Hiroki Hara received research funding from Chugai, Merck Sharp & Dohme, Ono Pharmaceutical, Eli Lilly, Taiho, Sumitomo Dainippon Pharma, Daiichi Sankyo, Merck Serono, AstraZeneca, Boehringer, LSK, Incyte, Eisai, and BeiGene, and honoraria from Chugai, Merck Sharp & Dohme, Ono/Bristol-Myers Squibb, Eli Lilly, Taiho, Daiichi Sankyo, Merck Serono, Takeda, and Sanofi; Tomohiro Nishina and Ayumu Hosokawa received research funding from Chugai; Takashi Asakawa and Satoe Kawakami are employees of Chugai Pharmaceutical Co., Ltd; Kei Muro received honoraria from Chugai, Takeda, Eli Lilly, Taiho, Ono, Bayer, Sanofi, and Bristol-Myers Squibb and research funding from Gilead Sciences, Merck Serono, Merck Sharp & Dohme, Daiichi Sankyo, Sanofi, Ono, Shinogi, Pfizer and Kyowa Hakko. Takaki Yoshikawa and Kazumasa Fujitani have no conflicts of interest.